SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2001.

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO _____.

Commission File Number 0-18592

MERIT MEDICAL SYSTEMS, INC.
(Exact name of Registrant as specified in its charter)

Utah	87-0447695
(State or other jurisdiction of incorporation or organization)	(I.R.S. Identification No.)

1600 West Merit Parkway, South Jordan UT, 84095
(Address of Principal Executive Offices)

(801) 253-1600
(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No

Indicate the number of shares outstanding of each of the Registrant's classes of common stock, as of the latest practicable date.

Common Stock	7,883,055
TITLE OR CLASS	Number of Shares Outstanding at May 14, 2001

MERIT MEDICAL SYSTEMS, INC.

INDEX TO FORM 10-Q

MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED BALANCE SHEETS
MARCH 31, 2001 AND DECEMBER 31, 2000

ASSETS	March 31, 2001	December 31, 2000
	(Unaudited)	
CURRENT ASSETS:		
Cash and cash equivalents	$ 469,092	$ 412,384
Trade receivables - net	14,372,128	13,235,858
Employee and related party receivables	406,603	440,654
Irish Development Agency grant receivable	46,617	177,477
Inventories	23,123,591	25,273,428
Prepaid expenses and other assets	900,658	663,101
Deferred income tax assets	1,183,944	1,183,944
Income tax refund receivable	238,958	588,640
Total current assets	40,741,591	41,975,486
PROPERTY AND EQUIPMENT:		
Land	1,260,985	1,260,985
Building	1,500,000	1,500,000
Manufacturing equipment	21,141,914	19,696,550
Automobiles	91,496	131,036
Furniture and fixtures	9,632,975	9,576,084
Leasehold improvements	5,456,297	5,420,194

Construction-in-progress	1,564,479	2,120,671
Total	40,648,146	39,705,520
Less accumulated depreciation and amortization	(18,788,557)	(17,860,490)
Property and equipment - net	21,859,589	21,845,030
OTHER ASSETS:		
Patents & trademarks - net	2,584,214	2,522,384
Deposits	38,859	41,273
Cost in excess of the fair value of assets of acquired-net	4,987,993	5,062,458
Total other assets	7,611,066	7,626,115
TOTAL ASSETS	$ 70,212,246	$ 71,446,631

(Continued)
See Notes to Consolidated Financial Statements

MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED BALANCE SHEETS
MARCH 31, 2001 AND DECEMBER 31, 2000

LIABILITIES AND STOCKHOLDERS' EQUITY	March 31, 2001	December 31, 2000
	(Unaudited)	
CURRENT LIABILITIES:		
Current portion of long-term debt	$ 872,428	$ 1,091,725
Trade payables	4,557,909	4,835,517
Accrued expenses	5,113,941	3,471,039
Advances from employees	138,206	96,778
Income taxes payable	318,872	33,420
Total current liabilities	11,001,356	9,528,479
DEFERRED INCOME TAX LIABILITIES	2,210,088	2,177,833
LONG-TERM DEBT	20,061,415	24,011,778
DEFERRED CREDITS	914,012	955,839
Total Liabilities	34,186,871	36,673,929
STOCKHOLDERS' EQUITY:		
Preferred stock- 5,000,000 shares authorized as of March 31, 2001 and December 31, 2000, respectively, no shares issued		
Common stock- no par value; 20,000,000 shares authorized; 7,801,988 and 7,788,208 shares issued at March 31, 2001 and December 31, 2000, respectively	19,888,904	19,779,765
Accumulated other comprehensive loss	(667,029)	(624,138)
Retained earnings	16,803,500	15,617,075
Total stockholders' equity	36,025,375	34,772,702
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 70,212,246	$ 71,446,631

See Notes to Consolidated Financial Statements

MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2001 AND 2000 (Unaudited)

	March 31, 2001	March 31, 2000
NET SALES	$ 26,788,373	$ 22,080,435
COST OF SALES	17,568,999	14,446,385
GROSS PROFIT	9,219,374	7,634,050
OPERATING EXPENSES:		
Selling, general and administrative	6,006,073	6,338,539
Research and development	1,130,072	1,005,936
TOTAL OPERATING EXPENSES	7,136,145	7,344,475
INCOME FROM OPERATIONS	2,083,229	289,575
OTHER EXPENSE - NET	436,067	517,404
INCOME (LOSS) BEFORE INCOME TAXES	1,647,162	(227,829)
INCOME TAX EXPENSE (BENEFIT)	460,737	(68,347)
NET INCOME (LOSS)	$ 1,186,425	$ (159,482)
EARNINGS (LOSS) PER COMMON SHARE - Basic and diluted	$ .15	$ (.02)
AVERAGE COMMON SHARES -		
Basic	7,795,253	7,622,918
Diluted	7,894,084	7,893,646

See Notes to Consolidated Financial Statements

MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2001 AND 2000 (Unaudited)

	March 31, 2001	March 31, 2000
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income (loss)	$ 1,186,425	$ (159,482)
Adjustments to reconcile net income to net		

cash provided by (used in) in operating activities:		
Depreciation and amortization	1,112,130	1,081,220
Bad debt expense	59,417	390,780
Gain on sales and abandonment of property and equipment	(1,679)	
Amortization of deferred credits	(34,710)	(32,832)
Deferred income taxes	32,255	29,435
Changes in operating assets and liabilities:		
Trade receivables	(1,195,687)	(1,035,235)
Employee and related party receivables	34,051	(34,375)
Irish Development Agency grant receivable	123,743	8,751
Inventories	2,149,837	(880,489)
Prepaid expenses and other assets	(237,557)	(292,230)
Deposits	2,414	(59,970)
Trade payables	(277,608)	(762,655)
Accrued expenses	1,642,902	1,086,493
Advances from employees	41,428	21,843
Income taxes payable	635,134	(276,511)
Total adjustments	4,087,749	(757,454)
Net cash provided by (used in) operating activities	5,274,174	(916,936)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Capital expenditures for:		
Property and equipment	(743,856)	(1,152,049)
Intangible assets	(99,029)	(127,701)
Proceeds from sale of property and equipment	985	
Net cash used in investing activities	(842,885)	(1,278,765)

Continued on page 5
See Notes to Consolidated Financial Statements

MERIT MEDICAL SYSTEMS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
FOR THE THREE MONTHS ENDED MARCH 31, 2001 AND 2000 (Unaudited)

	March 31, 2001	March 31, 2000
CASH FLOWS FROM FINANCING ACTIVITIES:		
Borrowings under line of credit		1,700,576
Proceeds from issuance of common stock	109,139	950,608
Principal payments on:		
Long-term debt	(4,440,829)	(336,646)
Net cash provided by (used in) financing activities	(4,331,690)	2,314,538
EFFECT OF EXCHANGE RATES ON CASH	(42,891)	(36,178)
NET INCREASE IN CASH	56,708	82,659
CASH AT BEGINNING OF PERIOD	412,384	668,711
CASH AT END OF PERIOD	$ 469,092	$ 751,370

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:		
Cash paid during the period for:		
Interest (including capitalized interest of $16,771 and $27,037, respectively)	$ 70,792	$ 110,186
Income taxes	$ 118,360	$ 202,327

SUPPLEMENTAL DISCLOSURE OF NONCASH
INVESTING AND FINANCING ACTIVITIES:

During the three month periods ended March 31, 2001 and 2000, the Company entered into notes payable totaling $271,169 and $509,963 respectively, for manufacturing equipment and furniture and fixtures.

See Notes to Consolidated Financial Statements

MERIT MEDICAL SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

1. Basis of Presentation. In the opinion of management, the accompanying consolidated financial statements contain all adjustments, consisting only of normal recurring accruals, necessary for a fair presentation of the financial position of the Company as of March 31, 2001 and December 31, 2000, and the results of its operations and cash flows for the three months ended March 31, 2001 and 2000. The results of operations for the three months ended March 31, 2001 and 2000 are not necessarily indicative of the results for a full year period.

2. Inventories. Inventories at March 31, 2001 and December 31, 2000 consisted of the following:

	March 31, 2001	December 31, 2000
Raw materials	$ 8,527,737	$ 8,325,314
Work-in-process	3,792,119	3,678,807
Finished goods	12,845,048	15,255,622
Less reserve for obsolete inventory	(2,041,313)	(1,986,315)
Total	$ 23,123,591	$ 25,273,428

3. Income Taxes. The Company has not fully allocated income tax expense between current and deferred for the quarters ended March 31, 2001 and 2000. The effective tax rate for the three months ended March 31, 2001 and 2000 is below the 35% federal statutory tax rate, as the result of increased researched tax credits now available and the Company's profitable operations in Ireland which are taxed at a tax rate that is lower than the Company's U.S. overall effective rate.

4. Reporting Comprehensive Income - In June 1997, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No.130, "Reporting Comprehensive Income." SFAS No. 130 establishes standards for reporting and display of comprehensive income and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements. This statement requires that an enterprise (a) classify items of other comprehensive income by their nature in a financial statement and (b) display the accumulated balance of other comprehensive income separately from retained earnings and additional paid-in-capital in the equity section of a statement of financial position.

Effective January 1, 1998, the Company adopted the provisions of SFAS No. 130. Accordingly, the Company determined that the only transaction considered to be an additional component of comprehensive income is the cumulative effect of foreign currency translation adjustments. As of March 31, 2001 and December 31, 2000, the cumulative effect of such transactions reduced stockholders' equity by approximately $667,029 and $624,138, respectively. Comprehensive income for the three months ended March 31, 2001 and 2000 is computed as follows:

	Three Months Ended March 31, 2001	Three Months Ended March 31, 2000
Net Income (loss)	$ 1,186,425	$ (159,482)
Foreign currency translation	(42,891)	(36,178)
Comprehensive income (loss)	$ 1,143,534	$ (195,660)

5. Recently Issued Financial Accounting Standards - Statement of Financial Accounting Standards No.133, Accounting for Derivative Instruments and Hedging Activities, as amended, requires that all derivative instruments be recognized as either assets or liabilities at fair market value. The Company adopted this statement beginning January 1, 2001. The effect on the Company's financial statements of adopting this statement was not significant.

ITEM 2:

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

Merit Medical Systems enjoyed its best quarter in history, experiencing record revenues and earnings. The Company's sales increased across almost all of its product lines and distribution areas, particularly in kits to packers and OEM sales. The increased sales seem to come from a broad-based increase in customer ordering patterns. The Company believes that this level of increase may be temporary.

Management is happy to report that the new, comprehensive software system has moved from being a major challenge to an asset. With this Oracle software as a valuable tool and with the plan that management put in motion starting in the first quarter of 2000, we have made major progress in the efficiency and profitability of our Salt Lake operations. The result has been a tremendous improvement from a situation of large, unapplied overheads in the first quarter of 2000, to significant positive overhead variances for this quarter. If sales volumes continue to grow, and with inventories at much more manageable levels, these positive variances bode well for improved margins in the future.

The Company is seeing real opportunities to leverage the sales, general and administration and research and development strengths of the Company. Merit is also significantly reducing its inventory, debt balances, interest costs, as well as effective tax rates all of which are contributing to a much improved bottom line.

With the decline in inventories and its associated increase in inventory turns, and with a significant drop in long term debt, the Company has more capital available to invest in growth. Whether it be through new internal product development, acquisitions or distribution agreements, management has seen an increase in interesting, viable technology and/or product acquisition opportunities.

Operations. The Company's sales increased to record levels for the three months ended March 31, 2001 compared to the same period in 2000. The Company also experienced record earnings of $1.2 million for the three months ended March 31, 2001, compared to a net loss of $159,482 for the same period of 2000. The following table sets forth certain operational data as a percentage of sales for the three months ended March 31, 2001 and 2000:

	Three Months Ended March 31, 2001	Three Months Ended March 31, 2000
Sales	100.0 %	100.0%
Gross Profit	34.4	34.6
Selling, general and administrative	22.4	28.7
Research and development	4.2	4.6
Income From Operations	7.8	1.3
Other Expense	1.6	2.3
Net Income (Loss)	4.4	(.7)

Sales. Sales for the first quarter of 2001 increased by 21.4%, or $4,707,938, compared to the same period for 2000. This increase is due to sales volume increases across most of the companies product families. The Company experienced increased sales of many of its custom kits (up 32%). To a lesser degree, this increase was attributable to growth in sales of inflation devices (up 16%), stand alone products (up 22%) and catheters up (11%).

Gross Profit. Gross profit as a percentage of sales decreased slightly in the first quarter of 2001 to 34.4% as compared to 34.6% in the first quarter of 2000. The Company's margins are improving after the past three quarters of working through the overhead and efficiency deficits in the Salt Lake core operations unit. Continued improvements are still possible at the Angleton plant which continues to have excess inventory, overhead and capacity that negatively effect margins, but the negative variances are beginning to shrink.

Operating Expenses. Operating expenses decreased significantly as a percentage of sales to 26.6% of sales in the first quarter of 2001 compared to 33.3% in the first quarter of 2000. Selling, general and administrative costs as a percentage of sales decreased to 22.4%, in 2001, compared to 28.7% for the first quarter of 2000. The decrease as a percentage of sales in the current period was due primarily to a 5.2% decline in expense while sales increased significantly. Part of the comparative decline was due to the recognition in the first quarter of 2000 of an unusual bad debt as a result of one of the Company's larger customers going insolvent. Research and development expenses rose by $124,136 and were 4.2% of sales in the first quarter of 2001 compared to 4.6% of sales for the first quarter of 2000. This increase in expense was due primarily to the increased research & development resources associated with the new diagnostic wire project in Ireland.

Income. During the quarter ended March 31, 2001, the Company reported income from operations of $2,083,229, and increase of 619% from income from operations of $289,525 for the comparable period in 2000. The increase in operating income for the most recent quarter was attributable primarily to increased sales while selling, general & administrative expenses declined. Lower debt balances and interest rates are helping decrease interest expense. This combined for a net income of $1,186,425 for the quarter ended March 31, 2001 compared to a net loss of $159,482 for the same quarter of 2000.

Liquidity and Capital Resources. At March 31, 2001, the Company's working capital was $29,740,235, which represented a current ratio of 3.7 to 1. In March 2001, in an effort to reduce bank fees, the Company decreased an available secured bank line of credit to $22 million. At March 31, 2000, the outstanding balance under the line of credit was $19,000,000. As of May 11, 2001 the line of credit balance has been reduced to $16,846,760, or a reduction of over $13.5 million in less than nine months. Historically, the Company has incurred significant expenses in connection with product development and introduction of new products. Substantial capital has also been required to finance growth in inventories and receivables. The Company's principal source of funding for these and other expenses has been the sale of equity and cash generated from operations, secured loans on equipment and bank lines of credit. The Company believes that its present sources of liquidity and capital are adequate for its current operations.

Forward-Looking Statements. This Report includes "Forward-Looking Statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange of 1934, as amended. All statements other than statements of historical fact are "Forward-Looking Statements" for purpose of these provisions, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives of management for future operations, any statements concerning proposed new products or services, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. All Forward-Looking Statements included in this document are made as of the date hereof and are based on information available to Merit as of such date. Merit assumes no obligation to update any Forward- Looking Statement. In some cases, Forward-Looking Statements can be identified by the use of terminology such as "may," "will," "expects," "plans," "anticipates," "intends," or "believes," "estimates," "potential," or "continue," or the negative thereof or other comparable terminology. Although the Company believes that the expectations reflected in the Forward-Looking Statements contained herein are reasonable, there can be no assurance that such expectations or any of the Forward-Looking Statements will prove to be correct, and actual results could differ materially from those projected or assumed in the Forward-Looking Statements. Future financial condition and results of operations, as well as any Forward-Looking Statements are subject to inherent risks and uncertainties, including market acceptance of the Company's products, product introductions, potential product recalls, delays in obtaining regulatory approvals, cost increases, fluctuations in and obsolescence of inventory, price and product completion, availability of

labor and materials, development of new products and techniques that render the Company's products obsolete, foreign currency fluctuation, changes in health care markets related to health care reform initiatives and other factors referred to in the Company's press releases and reports filed with the Securities and Exchange Commission. All subsequent Forward-Looking Statements attributable to the Company or person acting on its behalf are expressly qualified in their entirety by these cautionary statements.

ITEM 3:

QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK

The Company principally hedges the following EURO currencies: Belgian Francs, French Francs, German Marks, Dutch Gilders, and Irish Pounds. The Company enters into forward foreign exchange contracts to protect the Company from the risk that the eventual net dollar cash flows resulting from transactions with foreign customers and suppliers may be adversely affected by changes in currency exchange rates. Such contracts are not significant. The Company does not invest in hedges for speculative proposes.

PART II - OTHER INFORMATION

ITEM 6: Exhibits and Reports on Form 8-K

(a) Exhibits	Exhibit No.	Description

1	Amendment to Loan Agreement with Zions First National Bank dated March 14, 2001

(b) Reports on Form 8-K - The Company filed a report on Form 8-K dated April 19, 2001 to report certain financial information for the quarter ended March 31, 2001 for the purpose of complying with Reg. F.D.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MERIT MEDICAL SYSTEMS, INC.
REGISTRANT

Date: May 14, 2001 BY: /S/ FRED P. LAMPROPOULOS

FRED P. LAMPROPOULOS
PRESIDENT AND CHIEF EXECUTIVE OFFICER

Date: May 14, 2001 BY: /S/ KENT W. STANGER

KENT W. STANGER
SECRETARY AND CHIEF FINANCIAL OFFICER

SECOND AMENDMENT
TO LOAN AGREEMENT

This Second Amendment to Loan Agreement (the "Amendment") is made and entered into among Merit Medical Systems, Inc. ("Merit Medical"), Merit Holdings, Inc. ("Merit Holdings"), Sentir Semiconductor, Inc. ("Sentir") (Merit Medical, Merit Holdings and Sentir are collectively called "Borrowers") and Zions First National Bank ("Lender").

Recitals

1. Borrowers and Lender have entered in an Amended and Restated Loan Agreement dated August 11, 1999 (as previously amended, the "Agreement").

2. Borrowers and Lender desire to modify and amend the Agreement as provided herein.

Amendment

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrowers and Lender hereby agree and amend and modify the Agreement as follows:

1. Definitions. Except as otherwise expressly provided herein, terms assigned defined meanings in the Agreement shall have the same defined meanings in this Amendment.

2. Amended Definition. The definition of "Facility Amount" in Section 1.1 of the Agreement is amended in its entirety to read as follows:

"Facility Amount" means twenty-two million dollars ($22,000,000.00) as such amount is reduced by three hundred seventy-five thousand dollars ($375,000.00) on the last day of each quarter commencing with the quarter ending March 31, 2001.

3. Conditions to Effectiveness of Amendment. The amendments set forth above shall become effective, as of the date and year set forth below, on such date (the "Second Amendment Effective Date") when the following conditions shall have been satisfied in a form and substance acceptable to Lender:

a. This Amendment and all other documents contemplated by this Amendment to be delivered to Lender prior to funding have been fully executed and delivered to Lender.

b. All other conditions precedent provided in or contemplated by the Agreement, the Security Documents, or any other agreement or document have been performed.

c. As of the Second Amendment Effective Date, the following shall be true and correct: (1) all representations and warranties made by Borrowers in the Agreement are true and correct as of the Second Amendment Effective Date; and (2) no Event of Default has occurred under the Agreement and no conditions exist and no event has occurred, which, with the passage of time or the giving of notice, or both, would constitute an Event of Default under the Agreement.

All conditions precedent set forth in the Agreement, the Security Documents, or in any other document relating thereto are for the sole benefit of Lender and may be waived unilaterally by Lender.

4. Collateral. The Loan and the Promissory Note are secured by the collateral identified in, and contemplated by the Agreement, including, without limitation, the various Security Agreements, dated August 11, 1999, executed by the Borrowers, and by the Collateral described in Section 3.1 Collateral of the Agreement.

5. Representations and Warranties. Each Borrower hereby affirms and again makes the representations and warranties set forth in Article 5 Representations and Warranties as of the Second Amendment Effective Date. Each Borrower represents and warrants that there have been no changes to the Organizational Documents of such Borrower since August 11, 1999.

6. Authorization. Borrower represents and warrants that the execution, delivery, and performance by Borrowers of this Amendment and all agreements, documents, obligations, and transactions herein contemplated have been duly authorized by all necessary action on the part of such Borrower and are not inconsistent with such Borrower's Organizational Documents or any resolution of the Board of Directors of such Borrower, do not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract, or other instrument to which such Borrower is a party or by which it is bound, and that upon execution and delivery hereof and thereof, this Amendment will constitute legal, valid, and binding agreements and obligations of each Borrower, enforceable in accordance with their respective terms.

7. Payment of Expenses and Attorney's Fees. Borrowers shall pay all reasonable expenses of Lender relating to the negotiation, drafting of documents, and documentation of this Amendment, including, without limitation, reasonable attorney's fees and legal expenses. If such expenses are not promptly paid, Lender is authorized and directed, upon execution of this Amendment and fulfillment of all conditions precedent hereunder, to disburse a sufficient amount of the Loan proceeds to pay in full these expenses.

8. Agreement Remains in Full Force and Effect. Except as expressly amended or modified by this Amendment, the Agreement remains in full force and effect.

9. Counterpart Execution. This Amendment may be executed in several counterparts, without the requirement that all parties sign each counterpart. Each of such counterparts shall be an original, but all counterparts together shall constitute one and the same instrument.

10. Integrated Agreement; Amendment. This Amendment, together with the Agreement, the Promissory Note, Security Documents, and the other agreements, documents, obligations, and transactions contemplated by the Agreement and the Amendment, constitute the entire agreements and understandings between the parties and supersede all other prior and contemporaneous agreements and may not

be altered or amended except by written agreement signed by the parties. This Amendment and the Agreement shall be read and interpreted together as one agreement. PURSUANT TO UTAH CODE SECTION 25-5-4, BORROWERS ARE NOTIFIED THAT THESE AGREEMENTS ARE A FINAL EXPRESSION OF THE AGREEMENT BETWEEN LENDER AND BORROWERS AND THESE AGREEMENTS MAY NOT BE CONTRADICTED BY EVIDENCE OF ANY ALLEGED ORAL AGREEMENT. All other prior and contemporaneous agreements, arrangements and understandings between the parties hereto as to the subject matter hereof are, except as otherwise expressly provided herein, rescinded.

Dated: March 5, 2001

Lender:

Zions First National Bank

By:

Title:

Borrowers:

Merit Medical Systems, Inc.

By: /s/: KENT W. STANGER

KENT W. STANGER
Title: CFO

Merit Holdings, Inc.

By: /s/: KENT W. STANGER

KENT W. STANGER
Title: CFO

Sentir Semiconductor, Inc.

By: /s/: KENT W. STANGER

KENT W. STANGER
Title: CFO